Results 321 to 330 of about 1,044,728 (382)

Preclinical Drug Evaluation with Human Melanoma Xenografts

, 1988
In 1974 there was an increasing awareness at the National Cancer Institute of the U.S.A. that important drugs might have been missed by the conventional murine tumor screening system then employed. Differences in biochemistry and cell biology of murine vs. human tumors were increasingly well understood.
R. Osieka
semanticscholar   +3 more sources

A postgraduate course in preclinical drug evaluation.

Therapies, 2004
J. Atkinson
semanticscholar   +4 more sources

Evaluation of Nanoparticle Drug-Delivery Systems used in Preclinical Studies

Therapeutic Delivery, 2021
Multifunctional nanoparticles have been identified as a promising drug-delivery system for sustainable drug release. The structural and size tunability and disease-targeting ability of nanoparticles have made them more suitable for multiple drug loading and delivery, thereby enhancing therapeutic results through synergistic effects.
Nagaraja Sreeharsha, Nataraj Chitrapriya, Yoon Jung Jang, Vanaja Kenchappa   +3 more
openaire   +2 more sources

Preclinical evaluation of UC781 microbicide vaginal drug delivery

Drug Delivery and Translational Research, 2011
UC781 is a potent nonnucleoside reverse transcriptase inhibitor being investigated as a potential microbicide to prevent transmission of HIV-1 both vaginally and rectally. This study was designed to investigate the in vitro drug release, in vitro permeability/safety, and in vivo pharmacokinetics in rabbits of a vaginal gel prepared with micronized or ...
David R. Friend, Timothy J. McCormick, Gustavo F. Doncel, Meredith R. Clark   +3 more
openaire   +3 more sources

Bupropion-induced convulsions: Preclinical evaluation of antiepileptic drugs

Epilepsy Research, 2005
Bupropion, a unique, non-nicotine smoking cessation aid and an effective antidepressant, is well known to produce seizures following overdosing in humans. However, the experimental background for the usefulness of antiepileptic drugs in the protection against bupropion-induced convulsions has not been established yet.
Tomasz Mróz, Marian Wielosz, Piotr Tutka, Katarzyna Klucha, Malgorzata Piekarczyk   +4 more
openaire   +3 more sources

Evaluation of Drug Candidates for Preclinical Development [PDF]

, 2009
Evaluation of drug candidates for preclinical development , Evaluation of drug candidates for preclinical development , کتابخانه مرکزی دانشگاه علوم پزشکی ...
Chao Han, Charles B. Davis, Binghe Wang
openaire   +1 more source

Current development of integrated web servers for preclinical safety and pharmacokinetics assessments in drug development

Briefings Bioinform., 2020
In drug development, preclinical safety and pharmacokinetics assessments of candidate drugs to ensure the safety profile are a must. While in vivo and in vitro tests are traditionally used, experimental determinations have disadvantages, as they are ...
Yi Hsiao, Bo-Han Su, Y. Tseng
semanticscholar   +1 more source

Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach

Epilepsia, 2022
SummaryObjectivePharmacokinetics (PK) of a drug drive its exposure, efficacy, and tolerability. A thorough preclinical PK assessment of antiseizure medications (ASMs) is therefore essential to evaluate the clinical potential. We tested protection against evoked seizures of prototype ASMs in conjunction with analysis of plasma and brain PK as a proof-of-
Jeffrey A. Mensah, Kristina Johnson, Christopher A. Reilly, Karen S. Wilcox, Joseph E. Rower, Cameron S. Metcalf   +5 more
openaire   +2 more sources

Urokinase-Conjugated Magnetite Nanoparticles as a Promising Drug Delivery System for Targeted Thrombolysis: Synthesis and Preclinical Evaluation.

ACS Applied Materials and Interfaces, 2018
Mortality and disabilities as outcomes of cardiovascular diseases are primarily related to blood clotting. Optimization of thrombolytic drugs is aimed at the prevention of side effects (in particular, bleeding) associated with a disbalance between ...
A. Prilepskii, A. Fakhardo, A. Drozdov, V. Vinogradov, I. P. Dudanov, A. Shtil, Petr Bel'tyukov, A. Shibeko, E. Koltsova, Dmitry Y Nechipurenko, V. Vinogradov   +10 more
semanticscholar   +1 more source

NCI Specialized Procedures in Preclinical Drug Evaluations

2004
Agents now come to the U.S. National Cancer Institute (NCI) from many sources for preclinical evaluation and/or potential development (1). In most cases, experimental agents have limited antiproliferative data against a broad spectrum of human cancers, and these agents usually are then tested in the NCI’ s in vitro anticancer drug screen. Data from the
Michael C. Alley, Gurmeet Kaur, Sherman F. Stinson, Christine M. Pacula-Cox, Melinda G. Hollingshead   +4 more
openaire   +2 more sources